Glen Eagle Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Glen Eagle Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18	Closed	-$1.62K	–	947
2020 Q1	$1.62K	Hold	18	–	–	﹤0.01%	724
2019 Q4	$1.95K	Hold	18	–	–	﹤0.01%	781
2019 Q3	$1.76K	Hold	18	–	–	﹤0.01%	717
2019 Q2	$2.36K	Hold	18	–	–	﹤0.01%	686
2019 Q1	$2.43K	Hold	18	–	–	﹤0.01%	638
2018 Q4	$1.75K	Hold	18	–	–	﹤0.01%	637
2018 Q3	$2.5K	Hold	18	–	–	﹤0.01%	612
2018 Q2	$2.23K	Hold	18	–	–	﹤0.01%	600
2018 Q1	$2.01K	Buy	+18	New	+$2.15K	﹤0.01%	587
2017 Q4	–	Sell	-26	Closed	-$3.65K	–	682
2017 Q3	$3.65K	Buy	+26	New	+$3.53K	﹤0.01%	546

Other funds holding ALXN

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return